Kairos Pharma, LTD 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
AMEX
10-K/A: Kairos Pharma Amends Annual Report to Detail Executive Compensation and Corporate Governance
Kairos Pharma, Ltd. filed an amendment to its 2024 Annual Report to include detailed information on executive compensation, corporate governance, and related party transactions, ensuring SEC compliance.
AMEX
Kairos Pharma, Ltd. files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted exhibits related to securities description and executive compensation recovery policy.
AMEX
Kairos Pharma's 2024 10-K filing details the company's ongoing clinical trials, financial status, and strategic focus on developing cancer therapeutics.